<DOC>
	<DOCNO>NCT01091662</DOCNO>
	<brief_summary>This 18-week , double-blind , multicenter study gradual conversion previous antiepileptic therapy eslicarbazepine acetate monotherapy subject partial epilepsy .</brief_summary>
	<brief_title>Safety &amp; Efficacy Eslicarbazepine Monotherapy Sub.w/Partial Epilepsy Not Well Controlled Current Antiepileptic</brief_title>
	<detailed_description>This 18-week , double-blind , randomize , historical control , multicenter study gradual conversion monotherapy subject partial onset seizure well control current AEDs . The 18 week double-blind treatment period consist 2-week titration period , 6-week taper conversion period , 10-week monotherapy period . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>Diagnosis partial epilepsy define Classification Seizures International League Against Epilepsy ( ILAE ) ( simple partial seizure observable motor component , complex , without secondary generalization ) Medical history seizure ; Absence confound factor ( pseudoseizures , syncope ) ; Documented EEG recording ( do within 5 year prior screen ) consistent focal onset epilepsy Documented CT MRI scan conduct within 10 year prior screen , show absence structural abnormality ( eg , tumor malformation ) ≥ 4 partial onset seizures 8 week prior screen 28day seizure free period Stable treatment 12 AEDs last 4 week prior screen Subjects must ability comprehend informed consent form willing provide inform consent . For subject unable comprehend write consent , witness/caregiver able describe provide understand inform consent subject must sign consent form behalf subject . Subjects must give write informed consent prior participation study . For subject &lt; 18 year age , informed consent must sign subject 's parent legal guardian , , appropriate and/or require state local law , minor subject must give write informed assent prior participation study . Subjects Asian ancestry require give write informed consent genotyping . All subject must sign HIPAA Form . All female child bear potential must also sign `` Women Childbearing Potential '' Addendum . A female subject eligible enter participate study : Nonchildbearing potential ( ie , physiologically incapable become pregnant , include female premenarchal postmenopausal ) ; Childbearing potential ( females ≤65 year age ) , negative pregnancy test screen agrees satisfy contraception requirement Subjects simple partial seizure without motor component Presence generalize seizure syndrome ( eg , juvenile myoclonic epilepsy LennoxGastaut syndrome ) History pseudoseizures Current seizure relate acute medical illness Seizures secondary metabolic , toxic infectious disorder drug abuse Status epilepticus within 2 year prior screen Seizures occur cluster pattern Subjects take 2 follow sodium channel block AEDs : phenytoin , carbamazepine , oxcarbazepine , lamotrigine Subjects take 2 AEDs upper dose range ( define approximately twothirds define daily dose ) Subjects take 2 AEDs Subjects progressive structural central nervous system lesion progressive encephalopathy Psychiatric exclusion criterion Medical exclusion criterion : know renal insufficiency ( estimate creatinine clearance [ CrCL ] ) &lt; 60 mL/min base serum creatinine use CockcroftGault formula Clinical laboratory exclusion criterion : Subjects Asian ancestry test positive presence HLAB*1502 allele Subjects benzodiazepine , phenobarbital , primidone regular basis within 3 month prior screen Subjects take antipsychotic , tricyclic antidepressant , anxiolytic , sedative hypnotic include nonbenzodiazepines , central opioid agonists/antagonists , monoamine oxidase inhibitor ( MAOIs ) within least 5 half life ( least 2 week whichever longer ) prior randomization Subjects presently felbamate vigabatrin</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Seizures</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>Anticonvulsant</keyword>
	<keyword>Monotherapy</keyword>
	<keyword>Historical control</keyword>
</DOC>